diff --git a/docs/investmoz/simulations/integrated-review-continuation-20261020-receipt.json b/docs/investmoz/simulations/integrated-review-continuation-20261020-receipt.json
index 3925b5ee..9c76cd22 100644
--- a/docs/investmoz/simulations/integrated-review-continuation-20261020-receipt.json
+++ b/docs/investmoz/simulations/integrated-review-continuation-20261020-receipt.json
@@ -6819,5 +6819,163 @@
       "installed-public-delta.json": "25cf1ea0d7ad86488db226b8cf242b2f6ee79f7271650d236e4a37423c9d5a12",
       "manifest-served.json": "2f3fd204e659ac71f0e35b59365b7342d79f1460119ef34a4daa217e4b21c0af"
     }
+  },
+  "iva_l1_g2_pharma_inputs_qa_20261024": {
+    "candidate": "8882dc54d0973bc058b04009bdbc36c9da2cc31b",
+    "status": "demonstrated_QA_not_installed",
+    "base_homologation": "e45a1394fa2ca8631593549b3af62093f25d9c13",
+    "base_receipt": "eb9e0dbc",
+    "group": "G2K within G2",
+    "branches": {
+      "AUD-SIM-L1-P008": [
+        "pharma_manufacturing_inputs"
+      ]
+    },
+    "branch_count": 1,
+    "treatment_count": 1,
+    "annex_documentary_rows": 170,
+    "annex_distinct_codes": 169,
+    "annex_version": "annexIII-lei22-2022/1",
+    "annex_transcription_sha256": "861b660fc124f2e33cbefb30bdb2a0a9680c471d5c6ecfedc883c3a5fc81bdf7",
+    "sources": [
+      {
+        "path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\Lei-13-2016-CIVA-BR-156-10-suplemento.pdf",
+        "sha256": "b90dc7c14ecea2e378c4a62e8e5a47d54a5644c457baeb8b8053b92fd2a5710b",
+        "citations": [
+          "9(1)(g),PDF9/p1426(267)",
+          "19(1),PDF15/p1426(273)"
+        ]
+      },
+      {
+        "path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\BR-89-I-Serie-2017-06-08.pdf",
+        "sha256": "11f0cab15eb6e51010952203ffa24fdc533a24fd642e19525fe4f46b17a1f5e5",
+        "citations": [
+          "Annex rectification,PDF1/p569"
+        ]
+      },
+      {
+        "path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\Lei-22-2022-IVA-republicada-BR-250-2-suplemento.pdf",
+        "sha256": "ea1b0dc6f5cf6e595f6d9a19e7042f398999e0087caef1785f6e8fac571b5f53",
+        "citations": [
+          "art3(1),art6,PDF4/p2252(28)",
+          "AnexoIII PDF12-16/p2252(36)-(40)"
+        ],
+        "visual_pages_checked": [
+          12,
+          13,
+          14,
+          15,
+          16
+        ]
+      }
+    ],
+    "scope": "2026/MZN/07; internal transmission by the SNS-integrated public/private establishment itself; manufacturing use; cumulative code/designation; no automatic deduction or ATsubmission",
+    "new_optional_field": "pharmaAnnexItem; selected documentary row identity, not an inferred tariff code",
+    "documentary_identity": {
+      "duplicated_code": "2912.19.00",
+      "separate_ids": [
+        "annexIII-2022-084",
+        "annexIII-2022-085"
+      ],
+      "printed_position": "2935.",
+      "no_missing_digits_invented": true,
+      "continuation_pages_preserved": true,
+      "text_layer_correction": "Anitibióticos -> printed Antibióticos; original unchanged"
+    },
+    "tests": {
+      "new_frontend": 3,
+      "API_QA_tests": 1,
+      "API_QA_assertions": 27,
+      "UI_revision": 4,
+      "UI_search_preserves_selection": true,
+      "UI_missing_annex_indeterminate": true,
+      "UI_missing_transmitter_SNS_condition_indeterminate": true,
+      "UI_reload_preserves_state": true,
+      "UI_to_API_to_report": true,
+      "report_visual_HTML": true,
+      "types": "passed",
+      "build": "passed",
+      "accepted_Word_PDF_fraction_proofs": "reused;renderersunchanged;no new pagination claim"
+    },
+    "example": {
+      "scope": "opportunity:320",
+      "location": "Manica",
+      "period": "2026-12",
+      "currency": "MZN",
+      "rows": 5,
+      "07": "500.00",
+      "05": "0.00",
+      "VAT": "0.00"
+    },
+    "preservation": {
+      "delivered_branches": 34,
+      "matrix_delivered_rows_unchanged": true,
+      "frozen_books_unchanged_and_current_without_recalculation": 11,
+      "calendar_version": "production-option/2 unchanged",
+      "manual_accepted_tests_repeated": false,
+      "active_data_writes": 0,
+      "schema_or_permission_changes": false
+    },
+    "counts": {
+      "delivered": 34,
+      "demonstrated_QA": 1,
+      "functional_pending": 97,
+      "documentary_pending": 1,
+      "total": 133
+    },
+    "G2_counts": {
+      "total": 32,
+      "delivered": 30,
+      "QA": 1,
+      "functional_pending": [
+        "P035"
+      ]
+    },
+    "conditional_treatments_total": 73,
+    "indeterminate_options": 2,
+    "P001_scope": "05/06 only; not resolved",
+    "L1_complete": false,
+    "homologation_unchanged": true,
+    "statistics_AI": "deferred",
+    "new_source_acquisition": {
+      "path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\BR-95-I-Suplemento-2025-05-21.pdf",
+      "origin": "https://archive.gazettes.africa/archive/mz/2025/mz-government-gazette-series-i-supplement-dated-2025-05-21-no-95.pdf",
+      "sha256": "e0e682e2c027c3cd9c1d46a73a3f48bc5f6bdbf05667fd97314d7a3f6a456358",
+      "pages": 2,
+      "citations": [
+        "Lei3/2025art1,PDF1/p478(1):only9(13),term31Dec2025",
+        "PDF2/p478(2):9(13)f;art2publicationdate;AnexoII"
+      ],
+      "visual_checked": true,
+      "source_inventory": "existing inventario-fontes.csv, one row appended; previous rows unchanged",
+      "matrix_documentary_dependency_only": [
+        "P038",
+        "P039",
+        "P040",
+        "P041",
+        "P042",
+        "P043"
+      ],
+      "G3_implemented_or_activated": false,
+      "original_imported_or_published_in_active_database": false
+    },
+    "artifacts": {
+      "frontend-tests.txt": "c8a066cff1d311939cc03257251e096920290794c7b10cd0102b99593440c4d6",
+      "api-tests.xml": "a6eef076a6745b8e8e4fc3c7d8b8ad84c2b8d8f2edfdd234d20592a2b57ecfed",
+      "api-ui-tests.xml": "5c495881cce29615aaf24c3861bb343588106ab01ef98c60043afb7a2512c5dc",
+      "ui-calculated.json": "a094479ab5e6edeb880b69cf0b86b519dc4b78496a3013c94d0a68d8f66a5b76",
+      "recovered.json": "071216959dbea3c1df196ef1679b8bc0e287cda95ee754c7b25886a7da233067",
+      "pharma-model.json": "022b4ed5a60ecef92ee5a6d802f1afc6134439f43196e50e569881007e61324d",
+      "pharma-report.html": "edba8b3ba91956ed38ddaf2c5c73cdd44052d9412bfcb9348e8e166b209cca26",
+      "report-qa.png": "64b6634aac1a1f6a835ff96458db747d569e62267dc2800246fbe45f31d3648a",
+      "types.txt": "82962651e47f564de653ad2883f8fd34e7dae4b4468e4ac459cb3331962a3879",
+      "build.txt": "e80105992bba4531c0046d302cee2d71eb38a6f797af836eda33776e2365b646",
+      "annexIII-extracted.json": "8cc1678e2b6580ce64ddf56e291c7ba37b8702302a135480b500c8a0b13ce59d",
+      "annexIII-12.png": "8f5f68201651f2213db4d9d52916118785928d687ae794ee6dea5ce0eea27ec2",
+      "annexIII-13.png": "fdc9fc486b371876572c48af39d541325449f1aa8d8e77ad2650ed8f71ca621b",
+      "annexIII-14.png": "585afde16f8fac6608f0d1dbad412ffb296fb7d0bfd0f19ee6a5d226408000f9",
+      "annexIII-15.png": "5400e7104604e46e61e5af9005664abaab08e5c0330909f4b10d624a3da69489",
+      "annexIII-16.png": "c8af2c702e6e2f592987666bce00a09f7ec947ff8034f7c9e173f29774060c8c"
+    }
   }
 }
diff --git a/docs/investmoz/unification/traceability-and-manual.md b/docs/investmoz/unification/traceability-and-manual.md
index aa964a3e..1cc04fe0 100644
--- a/docs/investmoz/unification/traceability-and-manual.md
+++ b/docs/investmoz/unification/traceability-and-manual.md
@@ -2,7 +2,7 @@
 
 ## 24/10/2026 — G2K / P008 demonstrado em QA
 
-**Um ramo, um tratamento: `pharma_manufacturing_inputs`.** Homologação permanece em `e45a1394`, recibo `eb9e0dbc`; os34 ramos entregues, incluindo G2I/G2J e calendário, continuam encerrados. L1 aberto; P001 exclusivamente05/06. Estatísticas/IA adiadas.
+**Candidata `8882dc54d0973bc058b04009bdbc36c9da2cc31b`; um ramo, um tratamento: `pharma_manufacturing_inputs`.** Homologação permanece em `e45a1394`, recibo `eb9e0dbc`; os34 ramos entregues, incluindo G2I/G2J e calendário, continuam encerrados. L1 aberto; P001 exclusivamente05/06. Estatísticas/IA adiadas.
 
 ### Fonte, cobertura e correspondência executável